Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction

DHF Trial - Circulation, 2019 - utsouthwestern.elsevierpure.com
BACKGROUND: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …
被引用次数：1 相关文章

Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction

DHF Trial - Circulation, 2019 - scholars.northwestern.edu
BACKGROUND: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …

Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction

DHF Trial - Circulation, 2019 - mayoclinic.elsevierpure.com
BACKGROUND: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …

Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction

DHF Trial - Circulation, 2019 - profiles.wustl.edu
BACKGROUND: Outcome trials in patients with type 2 diabetes mellitus have demonstrated
reduced hospitalizations for heart failure (HF) with sodium-glucose co-transporter-2 …